Led · Series B · Jul 2025

Baraya delivers long-term care and rehabilitation services through outpatient clinics and planned inpatient facilities, targeting post-acute and extended-care patients. Launched in 2023, the company has opened two outpatient clinics in Riyadh and Jeddah. Baraya plans to admit patients to its first 216-bed long-term care and rehabilitation hospital by early 2026 and aims to scale capacity to approximately 650 beds in the coming years. The business is positioning a standardized, scalable model that the company says could be replicated in other markets such as Southeast Asia. The raise comes amid Saudi Arabia’s aging population and health-system pressures—currently 14% of acute care beds in public hospitals are occupied by long-stay patients (19% in Jeddah, 17% in Riyadh). Baraya’s recent financing is intended to fund network expansion of inpatient facilities and outpatient rehabilitation clinics across the Kingdom.

Participated · Equity · Feb 2025

neurocare is a Munich-based provider of a mental health platform that empowers clinicians to deliver personalized treatment across psychological and neurological conditions. Its platform embeds tools and methods such as sleep hygiene, rTMS, QEEG and neurofeedback alongside talk therapy and pharmaceuticals. These assets are integrated within a cloud-based solution designed to drive clinician productivity and improve clinical outcomes. Following a detailed assessment of a patient’s condition, the platform supports clinicians in developing individualized, scientifically backed therapy plans for Depression, ADHD, mental performance and other indications. The company intends to use recent funding to further develop its technologies and services and to expand the international footprint of its mental health clinics. neurocare is led by CEO Thomas Mechtersheimer and recently raised EUR 19.3M from external backers. neurocare provides an integrated, personalized treatment approach built around its Digital Therapy Platform (DTP), which supports clinicians in developing individualized therapy plans. The DTP combines psychotherapy, neuromodulation, sleep hygiene and medication to treat a variety of psychological and neurological conditions and to improve self-regulation, resilience and social skills. The platform is used in neurocare’s clinics across the US, the Netherlands and Australia, and is deployed in a growing number of third-party clinics. Led by CEO and founder Thomas Mechtersheimer, the company emphasizes clinically evidenced, cost-effective care for healthcare systems. neurocare plans to use the new funding to accelerate international growth — including US expansion and market entry into the Kingdom of Saudi Arabia — and to support development of new hardware and software innovations. The company recently raised EUR 16M to support these initiatives.

Led · Series B · Aug 2024

Human Longevity develops longevity-focused technologies and services centered on an artificial intelligence health risk and recommendation platform. It operates a 100+ Longevity Care membership program designed to identify early stages of major age-related diseases and to increase healthspan and lifespan via its clinical care team and data platform. The program leverages precision-medicine inputs including whole-genome sequencing, whole-body and brain MRI, comprehensive cardiac evaluations, body composition analysis, advanced blood biomarkers, and wearables. By continually adding and analyzing client health data, the company aims to shift care from reactive to proactive, preventative, and personalized. The company plans to invest in additional longevity technologies, services, and new expansion sites globally. Human Longevity is headquartered in San Francisco, CA. Human Longevity operates the Health Nucleus intelligence platform, which combines specialized imaging, whole genome sequencing and other lab tests with machine learning and AI to generate precision health analytics. The company provides in-depth Health Nucleus assessments in La Jolla, CA, delivering risk analyses for cardiac, cancer, metabolic and cognitive issues. Core inputs to the platform include whole genome sequencing, brain and body MRI, cardiac CT (CAT) scans, metabolic tests and additional diagnostics. Human Longevity positions these integrated metrics as a comprehensive standard for measuring health and performance for physicians and patients. The company announced a $30 million financing to support its operations. Proceeds from the financing will be used to enhance the Health Nucleus intelligence platform. Human Longevity, Inc. (HLI) is a San Diego, CA–based genomics company led by co-founder and CEO J. Craig Venter, Ph.D., that aggregates whole-genome, phenotype and clinical data. Its core offerings include the HLI Health Nucleus, a genomic-enhanced clinical research center that combines whole genome sequencing, advanced clinical imaging and machine learning. The company is developing large-scale computing and machine-learning approaches to discover novel insights in medicine. HLI operates the HLI Knowledgebase, which currently contains more than 20,000 complete genomes coupled with phenotype data. Its business also includes a Comprehensive Cancer Program and other sequencing programs. HLI plans to use new funding to grow and expand these products and continue development of the Knowledgebase.

Led · Equity · Jun 2024

Boston Oncology Arabia is a bio-generic drugs manufacturing company headquartered in Riyadh with a production facility in Sudair Industrial City that develops and manufactures internationally licensed therapeutics. The company provides vital medicines for critical conditions, focusing on specialty generics and biosimilar medications using already approved formulations to meet pharmaceutical quality, safety, and efficacy standards. It aims to increase local production to meet Saudi Arabia’s growing demand and contribute to Vision 2030 by supplying critical care medicines through flexible local manufacturing. TVM Capital Healthcare’s USD 35 million investment will support the company’s move into full formulation and fill-and-finish manufacturing at its Sudair facility and expand access to international suppliers. Management plans to leverage licensing relationships from Western and Eastern markets to bring best-in-class therapeutics to the GCC and MENA region and strengthen its position in oncology and critical care.

Led · Equity · Jun 2024

Boston Oncology Arabia develops and manufactures internationally licensed bio-generic and biosimilar therapeutics, supplying vital medicines for oncology and critical care. The company focuses on locally producing specialty generics and biosimilars using already approved formulations to meet pharmaceutical quality, safety, and efficacy standards. Its headquarters are in Riyadh and manufacturing is at a production facility in Sudair Industrial City. Boston Oncology Arabia’s localization model and international licensing relationships from Western and Eastern markets support expanded access to life-saving specialty drugs across the GCC and MENA region. The company positions itself to become a key Saudi provider of specialty generics and biosimilars and contributes to Saudi Vision 2030 by increasing local production and reducing healthcare costs. TVM Capital Healthcare’s involvement is expected to expedite the company’s move into full formulation and fill-and-finish manufacturing and to broaden its access to international suppliers and licensing partners.